Clinical Trials Logo

Filter by:
NCT ID: NCT02853058 Recruiting - Labor Complication Clinical Trials

Uterine Artery Pulsatility Index and Materno Fetal Outcomes

UADLAB
Start date: July 2016
Phase: N/A
Study type: Interventional

High Uterine artery index pulsatility (PI) is associated with small for gestationnal age but also with stillbirth and distress during labor.

NCT ID: NCT02847936 Recruiting - Episiotomy Clinical Trials

Efficacy of Triclosan-coated Sutures in the Episiotomy

EPISIOVIC
Start date: July 2016
Phase: Phase 4
Study type: Interventional

Surgical repair of perineal lesions after delivery can be associated with infection of the surgery site. The aim of this study was to compare the surgical site infection with triclosan-coated suture (Vicryl Plus) versus coated suture (Vicryl) in the episiotomy after delivery.

NCT ID: NCT02831140 Recruiting - Thoracic Surgery Clinical Trials

The Fast Track Rehabilitation in Thoracic Surgery

FTR-TS
Start date: January 2016
Phase: N/A
Study type: Interventional

This prospective, randomized study is designed to evaluate the effectiveness of postoperative care pathway using the Fast Track Rehabilitation protocol (FTR) in comparison with the traditional postoperative care. In order to conduct this study, patients having a thoracic surgery will be randomly attributed to FTR protocol group or control group.

NCT ID: NCT02708446 Recruiting - Clinical trials for Legally Induced Abortion Without Mention of Complication

A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion

Start date: May 2014
Phase: Phase 4
Study type: Interventional

The primary goal of this study is to directly compare repeat doses of sublingual and buccal routes of 400 mcg misoprostol following mifepristone for second trimester abortion in order to determine if sublingual route confers an advantage with respect to efficacy and median time to complete abortion.

NCT ID: NCT02544815 Recruiting - Acute Heart Failure Clinical Trials

Digoxin Short Term Treatment Assessment Randomized Trial in AHF

DIG-STA-AHF
Start date: May 1, 2023
Phase: Phase 3
Study type: Interventional

AHFS management is challenging and most of the used drugs has failed to decrease post-discharge mortality and readmission rates which represent the most important goal in AHFS. Digoxin processes many characteristics of a beneficial drug for heart failure, however recent publications has rose concerns about its safety profile and therefore decreasing its use. Whether digoxin is efficient and safe in short term treatment of acute heart failure is a question that should be studied.

NCT ID: NCT02055131 Recruiting - Thrombosis Clinical Trials

Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis

Start date: November 2013
Phase: Phase 4
Study type: Interventional

This is a prospective study consisting in testing whether systematic use of aspirin is beneficial for primary prevention of vascular access for hemodialysis attested by doppler ultrasound exam. The investigators will study aspirin resistance in the population of patients undergoing hemodialysis. The investigators will test sensibility of resistant patients to aspirin dose escalation. PFA-100 is the biologic test used in this study to define aspirin resistance.

NCT ID: NCT01880385 Recruiting - Clinical trials for Inflammatory Breast Cancer

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Beva
Start date: March 2011
Phase: Phase 1
Study type: Interventional

Multi-center, non randomised, open label, non controlled pilot study. Evaluating the treatment of bevacizumab in association with pre-operative chemotherapy, followed by surgery, adjuvant chemotherapy and radiotherapy in Patients with inflammatory breast cancer.

NCT ID: NCT00330447 Recruiting - Cancer Clinical Trials

Effects of Oncological Treatment During Pregnancy on Mother and Child

Start date: August 2005
Phase:
Study type: Observational [Patient Registry]

The researchers aim to investigate the outcome (overall survival) of mothers who are diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs, radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic examination).

NCT ID: NCT00207792 Recruiting - Clinical trials for Graft vs Host Disease

Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear. The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.

NCT ID: NCT00140829 Recruiting - Spastic Paraplegias Clinical Trials

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Spatax
Start date: July 2003
Phase: Phase 1
Study type: Observational

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network combines the experience of European clinicians and scientists working on these groups of diseases. Over the past year, they have assembled the largest collection of families and achieved a number of tasks (initiation of a clinical and genetic database, distribution of DNA to participating laboratories, mapping of three new loci, and refinement of several loci). In addition to clinicians from Europe and Mediterranean countries, who play a major role in collecting families according to evaluation tools developed and validated by the SPATAX members, the group includes major European laboratories devoted to the elucidation of the molecular basis of these disorders. Each laboratory will centralize all families with a subtype of autosomal recessive (AR) CA (n=116) or SP (n=207) in order to efficiently map and identify the responsible gene(s). Genome-wide scans are already underway in 61 families. Given the expertise of the participants, the researchers expect to map and identify several genes during the course of this project. The spectrum of mutations and phenotype/genotype correlations will be analysed thanks to this unique series of patients with various phenotypes. The knowledge gained will be immediately applicable to patients in terms of improved positive diagnosis, follow-up and appropriate genetic counselling. In the long term, models for genetic entity will be developed in order to understand the pathophysiology and to identify new targets for treatment. The series of patients assembled and the precise knowledge of natural history will facilitate the implantation of therapeutic trials based on rational approaches.